Cover Image

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma

Cancer immunotherapy has made unprecedented breakthrough in the fields of chimeric antigen receptor-redirected T (CAR T) cell therapy and immune modulation. Combination of CAR modification and the disruption of endogenous inhibitory immune checkpoints on T cells represent a promising immunotherapeut...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xingliang Guo (Author), Hua Jiang (Author), Bizhi Shi (Author), Min Zhou (Author), Honghong Zhang (Author), Zhimin Shi (Author), Guoxiu Du (Author), Hong Luo (Author), Xiuqi Wu (Author), Yi Wang (Author), Ruixin Sun (Author), Zonghai Li (Author)
Format:	Book
Published:	Frontiers Media S.A., 2018-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
by: Le Qin, et al.
Published: (2020)

PSCA is a target of chimeric antigen receptor T cells in gastric cancer
by: Di Wu, et al.
Published: (2020)

Biomarkers in individualized management of chimeric antigen receptor T cell therapy
by: Mengyi Du, et al.
Published: (2020)

Development of anti-PD-1 chimeric antigen receptor T cells to target a PD-1+ CD4 T cell population enriched in HIV provirus
by: K. Eichholz, et al.
Published: (2019)

Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
by: Alejandrina Hernández-López, et al.
Published: (2021)

Chimeric antigen receptor T cell therapy for multiple myeloma
by: Kana Hasegawa, et al.
Published: (2019)

Chimeric antigen receptor engineered cells and their clinical application in infectious disease
by: Chen Qian, et al.
Published: (2022)

The FDA's Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
by: Peter Marks
Published: (2019)

Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer
by: Ilnaz Rahimmanesh, et al.
Published: (2021)

Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment
by: Xuejia Kang, et al.
Published: (2024)

Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T‐Cell Therapy
by: Deni Hardiansyah, et al.
Published: (2019)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma
by: Maria Giraudo, et al.
Published: (2024)

Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression
by: Wei Jiang, et al.
Published: (2023)

Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells
by: Andrew M. Stein, et al.
Published: (2019)

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
by: Hamed Dabiri, et al.
Published: (2023)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
by: Zakaria Grada, et al.
Published: (2013)

Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery
by: Theodora Katopodi, et al.
Published: (2023)

The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy
by: Yuki Fujiwara, et al.
Published: (2022)

Chimeric antigen receptor T-cell as a significant player in the innovative treatment of hematological cancers
by: Karolina Makowska, et al.
Published: (2023)

Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
by: Zixun Yin, et al.
Published: (2021)

Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy
by: Beatrice Spokeviciute, et al.
Published: (2024)

Current status and future prospects of chimeric antigen receptor-T cell therapy in lymphoma research: A bibliometric analysis
by: Lijia Ou, et al.
Published: (2023)

Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir
by: Madhu C. Choudhary, et al.
Published: (2022)

Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing
by: Qibin Liao, et al.
Published: (2020)

Sculpting nursing resilience: Transforming lives, nurturing ethics in chimeric antigen receptor T‐cell therapy
by: Pranay Bende
Published: (2024)

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
by: Shinichi Makita, et al.
Published: (2019)

Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
by: Javad Masoumi, et al.
Published: (2021)

CD44‐targeted chimeric antigen receptor‐T eradicates acute myeloid leukaemic stem cells
by: Linah A. Shahoumi
Published: (2022)

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
by: Johannes Kast, et al.
Published: (2022)

Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study
by: Zihan Guo, et al.
Published: (2024)

CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors
by: Vanesa Alonso-Camino, et al.
Published: (2013)

BAY 60-6583 Enhances the Antitumor Function of Chimeric Antigen Receptor-Modified T Cells Independent of the Adenosine A2b Receptor
by: Jiaxing Tang, et al.
Published: (2021)

Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023
by: Wangshu Li, et al.
Published: (2024)

Sudden-onset painful eruption of the hands: A cutaneous chimeric antigen receptor T-cell therapy reaction
by: Jimena A. Miranda, MD, et al.
Published: (2023)

Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects
by: Zhaozhao Chen, et al.
Published: (2024)

Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy
by: Sarah M. Larson, et al.
Published: (2017)

Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
by: Riegler LL, et al.
Published: (2019)

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo
by: Qibin Liao, et al.
Published: (2020)

Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma
by: Liqing Kang, et al.
Published: (2020)

Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023
by: Ming-Yao Sun, et al.
Published: (2023)